Jounce Therapeutics, Inc. (JNCE) Stock Analysis
DELISTED 2023
What happened to Jounce Therapeutics, Inc. (JNCE) stock?
Jounce Therapeutics, Inc. (JNCE) no longer trades on public markets. It was delisted in May 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- May 2023
- Last recorded price (historical):
- $1.88 (last quote on record before the May 2023 delisting; historical, not a current quote)
Market cap $99.0M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Jounce Therapeutics, Inc. (JNCE). Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company focused on developing novel cancer treatments. Their pipeline includes monoclonal antibodies targeting key proteins on T cells and macrophages to enhance the body's immune response against tumors.
Last analyzed: Jun 13, 2026Jounce Therapeutics, Inc. (JNCE) Healthcare & Pipeline Overview
More about this archive record
Can I still buy JNCE shares?
No. JNCE stopped trading on public markets in May 2023, so the shares are not available through a broker. Anything you see quoted for JNCE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before JNCE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Jounce Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.